CTLA4 and hepatocellular carcinoma: Combination of a PD-L1 inhibitor with TIM-3, LAG-3, or CTLA-4 inhibitor led to an upregulated in vitro tumor-infiltrating lymphocyte (TIL) response of HCC-derived T cells (Zhou et al., 2017).